PeptidePedia The community reference

Special:RecentChanges

Change log·7,183 revisions·page 5 of 72

Every change to PeptidePedia Wiki, newest first. N marks a new page, m a minor edit and b an edit by an approved bot. The byte figure is the page size after the edit; the coloured figure is the change. 7,183 changes are logged in total.

7,183Logged changes
598Bot edits
175Page creations
256Active editors

18 June 2026

  1. (diff | hist) m b 14:40 Peptide 6,813 ±0 ArchiveBot (talk | contribs) bot: flag bare reference [rollback]
  2. (diff | hist) 14:05 Talk:Baseline laboratory panel 748 +117 LabRangeLindy (talk | contribs) /* Regression to the mean */ reply
  3. (diff | hist) 11:59 Tianjin Finder Chemical 14,449 ±0 VerifyVesna (talk | contribs) add the see-also to the certificate-of-analysis article [rollback]
  4. (diff | hist) 11:10 Talk:Lot traceability 674 +165 FreightFenna (talk | contribs) /* Consolidated shipments */ new section
  5. (diff | hist) m 10:59 Deamidation 5,263 ±0 BiosimilarBoaz (talk | contribs) add the peptide-content point: area percent alone cannot give a mass [rollback]
  6. (diff | hist) 10:30 Talk:Baseline laboratory panel 537 +154 PlainNumbersPip (talk | contribs) /* Regression to the mean */ new section
  7. (diff | hist) 09:53 Lot traceability 5,317 ±0 AnalyticalAnnie (talk | contribs) expand §What a lot is [rollback]
  8. (diff | hist) m 09:19 Test report forgery 5,391 ±0 KPV_Kester (talk | contribs) give the fields a compendially-complete certificate would carry [rollback]
  9. (diff | hist) 09:03 VendorInvestigate 5,067 ±0 LedgerLysander (talk | contribs) label the community tally as self-reported at this point of use as well [rollback]
  10. (diff | hist) m 08:49 Nantong Guangyuan Chemical 15,114 ±0 EndotoxinEd (talk | contribs) add the standing talk-page note link to the banner [rollback]
  11. (diff | hist) 07:38 LEADER trial 4,799 ±0 DiluentDiya (talk | contribs) add the comparator arm — an event rate alone says nothing [rollback]
  12. (diff | hist) m 07:33 Weight regain after discontinuation 4,670 ±0 WeaselWordWim (talk | contribs) give the incidence with its denominator [rollback]
  13. (diff | hist) m 03:45 Good manufacturing practice 5,123 ±0 HarmReductionHen (talk | contribs) add the cross-link to the legal-status-by-jurisdiction list [rollback]
  14. (diff | hist) 01:04 Area percent purity 8,537 ±0 NewLabNell (talk | contribs) correct the integration description — valley-to-valley, not drop-line [rollback]

17 June 2026

  1. (diff | hist) 20:23 USP General Chapter 85 5,180 ±0 IpamorelinIsold (talk | contribs) add the equilibration time to the gradient description [rollback]
  2. (diff | hist) m b 18:12 Medutest 5,018 ±0 ArchiveBot (talk | contribs) bot: normalise citation format [rollback]
  3. (diff | hist) 17:47 Active pharmaceutical ingredient 4,569 ±0 AnalyticalAnnie (talk | contribs) space between number and unit per PP:MOS [rollback]
  4. (diff | hist) m 17:41 Vial filling and stoppering 4,833 ±0 CDMO_Caradoc (talk | contribs) add the customs-detention point as a logistics fact, sourced [rollback]
  5. (diff | hist) m 16:25 Trifluoroacetate counterion 5,116 ±0 DiagramDelphine (talk | contribs) copyedit [rollback]
  6. (diff | hist) m 16:05 Semaglutide 10,355 ±0 UnitsUrsula (talk | contribs) add the excipient list from the labelling [rollback]
  7. (diff | hist) 15:33 Talk:Retatrutide 885 +151 RetatrutideRuben (talk | contribs) /* Heart-rate signal deserves more space */ reply
  8. (diff | hist) 11:46 Peptide content 8,404 ±0 AmylinAmos (talk | contribs) expand §How content is determined [rollback]
  9. (diff | hist) 11:27 Wuhan Wansheng Biotechnology 15,849 ±0 ArcuateArt (talk | contribs) fix the anchor on an internal link [rollback]
  10. (diff | hist) 11:15 Talk:Retatrutide 674 +213 SafetySignalSid (talk | contribs) /* Heart-rate signal deserves more space */ new section
  11. (diff | hist) m 10:24 SURPASS trial programme 5,078 ±0 StudentSindhu (talk | contribs) rm the survival claim — no mortality endpoint was pre-specified [rollback]
  12. (diff | hist) 06:29 Sangon Biotech 14,764 ±0 ChainCustodyChad (talk | contribs) convert the product range to a table so the documentation column lines up [rollback]
  13. (diff | hist) 06:08 Proglucagon 6,709 ±0 GlossaryGaspar (talk | contribs) ce [rollback]
  14. (diff | hist) m b 05:47 Peptide synthesis 5,649 ±0 StubSorterBot (talk | contribs) bot: update parent category chain [rollback]
  15. (diff | hist) 00:09 Cagrilintide 4,256 ±0 SurvodutideSaff (talk | contribs) expand §Design [rollback]

16 June 2026

  1. (diff | hist) 22:57 Oral semaglutide 4,582 ±0 SyringeSybille (talk | contribs) clarify that the peptide backbone is acylated rather than PEGylated [rollback]
  2. (diff | hist) m 22:24 Sharps disposal 16,357 +22 StabilityStig (talk | contribs) add the note about drawing air before withdrawal [rollback]
  3. (diff | hist) 21:23 Melanotan II 4,649 ±0 GHK_Gwendolen (talk | contribs) the article conflated two peptides with adjacent names; disambiguated [rollback]
  4. (diff | hist) 16:46 Patent expiry and biosimilars 4,553 ±0 ShortageShona (talk | contribs) state that research-use-only labelling is a commercial category, not an approval [rollback]
  5. (diff | hist) 15:00 Talk:Underfilling 885 +142 UnderfillUna (talk | contribs) /* Tare error on small fills */ reply
  6. (diff | hist) 14:40 Talk:Solid-phase peptide synthesis 885 +115 COA_Colwyn (talk | contribs) /* Process detail versus quality attributes */ reply
  7. (diff | hist) 13:55 Talk:International nonproprietary name 748 +74 MassSpecMarv (talk | contribs) /* A name is an assertion */ reply
  8. (diff | hist) 11:35 Talk:Underfilling 674 +193 BlankVialBo (talk | contribs) /* Tare error on small fills */ new section
  9. (diff | hist) 11:05 Talk:Solid-phase peptide synthesis 674 +183 GMP_Gita (talk | contribs) /* Process detail versus quality attributes */ new section
  10. (diff | hist) 10:20 Talk:International nonproprietary name 537 +125 VerifyVesna (talk | contribs) /* A name is an assertion */ new section
  11. (diff | hist) 08:14 Talk:Sharps disposal 1,170 +60 SafetySignalSid (talk | contribs) /* Hepatitis B figures are pre-vaccine and the table does not say so clearly enough */ reply
  12. (diff | hist) 03:00 Amylin 5,795 ±0 CuriousCallum (talk | contribs) attribute the potency comparison to the head-to-head trial rather than to two separate ones [rollback]
  13. (diff | hist) 02:48 Shanghai ERP Biotechnology 14,637 ±0 LipidLedgerLou (talk | contribs) state what the certificate supplied with orders carries [rollback]
  14. (diff | hist) 02:38 SELECT trial 5,171 ±0 EndpointEnid (talk | contribs) fix a broken wikilink [rollback]

15 June 2026

  1. (diff | hist) 20:32 Third-party testing 7,489 ±0 ColdChainCleo (talk | contribs) clarify that a QR code on a certificate proves issuance, not content [rollback]
  2. (diff | hist) 18:46 Regulatory status by jurisdiction 4,444 ±0 ImportPolicyIggy (talk | contribs) correct the description of the research-use-only exemption [rollback]
  3. (diff | hist) 18:42 Crude peptide 4,775 ±0 ReportReaderRilla (talk | contribs) rm the shipping recommendation — that is advice, not description [rollback]
  4. (diff | hist) 15:40 Reference standard 5,217 ±0 LyophilLena (talk | contribs) give the limit of quantitation with the signal-to-noise ratio it assumes [rollback]
  5. (diff | hist) 14:00 Talk:Aspiration risk under anaesthesia 748 +95 AnaesthesiaAoife (talk | contribs) /* Ultrasound measures the thing itself */ reply
  6. (diff | hist) 13:16 Liraglutide 5,967 ±0 MolarMassMaeve (talk | contribs) add the discontinued indication with its date [rollback]
  7. (diff | hist) 13:07 STEP trial programme 5,534 ±0 FormularyFrida (talk | contribs) add the discontinuation rate for adverse events in both arms [rollback]
  8. (diff | hist) 11:29 CagriSema 5,687 ±0 SurvodutideSaff (talk | contribs) the lead claimed weekly dosing for a compound dosed daily; corrected [rollback]
  9. (diff | hist) 10:51 Receptor bias 4,477 ±0 ReceptorRhoda (talk | contribs) clarify that the receptor is expressed outside the pancreas [rollback]
  10. (diff | hist) 10:25 Talk:Aspiration risk under anaesthesia 537 +120 ClinicCorrespondent (talk | contribs) /* Ultrasound measures the thing itself */ new section
  11. (diff | hist) 09:41 Talk:Sharps disposal 959 +275 SharpsSukhi (talk | contribs) /* Hepatitis B figures are pre-vaccine and the table does not say so clearly enough */ reply
  12. (diff | hist) m 08:24 GenScript Peptides 17,833 ±0 NavboxNiko (talk | contribs) expand the product-scope row in the infobox [rollback]
  13. (diff | hist) m 07:17 Beta cell function 6,096 ±0 ArcuateArt (talk | contribs) add the reference range with the assay it was established on [rollback]
  14. (diff | hist) 05:50 Placebo-adjusted effect 4,805 ±0 PreregPriya (talk | contribs) the trial was open-label; the article implied blinding [rollback]
  15. (diff | hist) 04:06 Dose escalation schedule 4,993 ±0 SharpsSukhi (talk | contribs) expand §Deviations and their consequences [rollback]

14 June 2026

  1. (diff | hist) 22:36 Custom peptide synthesis 4,773 ±0 AppendixAlva (talk | contribs) add the cross-link to the temperature-excursion article [rollback]
  2. (diff | hist) 22:07 C-peptide 4,400 ±0 LabRangeLindy (talk | contribs) rm the diagnostic threshold — the article describes, it does not diagnose [rollback]
  3. (diff | hist) 17:04 Timeline of incretin therapeutics 4,460 ±0 MolarMassMaeve (talk | contribs) add the discontinued indication with its date [rollback]
  4. (diff | hist) 15:29 Talk:Sharps disposal 748 +228 ClinicCorrespondent (talk | contribs) /* Hepatitis B figures are pre-vaccine and the table does not say so clearly enough */ reply
  5. (diff | hist) 15:10 Talk:PeptideMeter 885 +91 ScopeSeverin (talk | contribs) /* Small-sample rankings */ reply
  6. (diff | hist) 14:44 Reverse-phase HPLC 5,499 ±0 ColumnOvenCoy (talk | contribs) split overlong sentence [rollback]
  7. (diff | hist) 14:40 Talk:SELECT trial 885 +93 PlainNumbersPip (talk | contribs) /* NNT arithmetic */ reply
  8. (diff | hist) m b 14:07 Liquid chromatography-mass spectrometry 4,463 ±0 CategoryBot (talk | contribs) bot: sort category members [rollback]
  9. (diff | hist) m 13:17 Qingdao Sigma Chemical 15,455 ±0 Chromatokid (talk | contribs) fix hyphenation per PP:MOS [rollback]
  10. (diff | hist) 11:30 Talk:PeptideMeter 674 +151 DataTableDunja (talk | contribs) /* Small-sample rankings */ new section
  11. (diff | hist) 11:05 Talk:SELECT trial 674 +150 NNT_Nerys (talk | contribs) /* NNT arithmetic */ new section
  12. (diff | hist) 11:03 Talk:Sharps disposal 537 +345 SafetySignalSid (talk | contribs) /* Hepatitis B figures are pre-vaccine and the table does not say so clearly enough */ new section
  13. (diff | hist) 10:56 Arcuate nucleus 5,251 ±0 HalfLifeHavel (talk | contribs) add the species in which the knockout work was done [rollback]
  14. (diff | hist) m 07:11 Bacterial endotoxin test 5,317 ±0 Chromatokid (talk | contribs) add the repeatability figure with the number of injections [rollback]
  15. (diff | hist) 06:42 Methionine oxidation 5,001 ±0 Ref_Desk_Ron (talk | contribs) add the counterion determination method by name [rollback]
  16. (diff | hist) m b 05:42 Temperature excursion 24,964 ±0 StubSorterBot (talk | contribs) bot: normalise temperature formatting [rollback]
  17. (diff | hist) 02:32 Sharps disposal 16,335 +363 TrialsTabitha (talk | contribs) state the syringe graduation the unit figure assumes [rollback]
  18. (diff | hist) 00:38 Analytical method validation 5,342 ±0 Retention_Time_Rae (talk | contribs) add the figure for the chromatogram and caption its axes [rollback]

13 June 2026

  1. (diff | hist) 22:10 Residual solvent 5,085 ±0 EndpointEnid (talk | contribs) add the equilibration time to the gradient description [rollback]
  2. (diff | hist) 18:01 FLOW trial 4,583 ±0 ResolutionRoo (talk | contribs) state the analysis population: intention-to-treat or per-protocol [rollback]
  3. (diff | hist) 17:26 Guangzhou JEEP Biotechnology 15,452 ±0 LotTraceLuka (talk | contribs) split §Operations from §Product range [rollback]
  4. (diff | hist) m 15:53 PolyPeptide Group (Hangzhou) 18,363 ±0 VerifyVesna (talk | contribs) clarify that a registered business scope is a licensing fact, not a quality assurance [rollback]
  5. (diff | hist) 14:40 Talk:Gastric emptying 885 +121 QuietQuill (talk | contribs) /* Self-referential oral semaglutide point */ reply
  6. (diff | hist) 13:39 Albumin binding half-life extension 6,399 ±0 ReceptorRhoda (talk | contribs) unpipe a link that did not need piping [rollback]
  7. (diff | hist) 11:05 Talk:Gastric emptying 674 +129 OralSemaOswin (talk | contribs) /* Self-referential oral semaglutide point */ new section
  8. (diff | hist) 10:52 Electrospray ionisation 4,323 ±0 Areapercent_Ayo (talk | contribs) sentence case in headings per PP:MOS [rollback]
  9. (diff | hist) 07:32 Survodutide 5,445 ±0 ArchiveAudit (talk | contribs) state which salt form the mass in the infobox refers to [rollback]
  10. (diff | hist) 06:15 GLP-1 receptor 7,570 ±0 GreyMarketGreer (talk | contribs) correct the direction of the effect on gastric emptying [rollback]
  11. (diff | hist) 06:03 Fasting insulin 4,198 ±0 CagriCass (talk | contribs) fix the anchor on an internal link [rollback]
  12. (diff | hist) 02:19 Missed dose 5,277 ±0 NPOV_Nadia (talk | contribs) state the syringe graduation the unit figure assumes [rollback]
  13. (diff | hist) 00:33 Sigma-Aldrich (Shanghai) Trading 18,641 ±0 KPV_Kester (talk | contribs) split §Operations from §Product range [rollback]

12 June 2026

  1. (diff | hist) 23:59 High-performance liquid chromatography 7,231 ±0 ChromCleanupCass (talk | contribs) add the detection wavelength [rollback]
  2. (diff | hist) 23:05 Tirzepatide 8,037 ±0 MolarMassMaeve (talk | contribs) convert the substitution list to a table so the analogues line up [rollback]
  3. (diff | hist) m 22:29 Sterility testing 4,776 ±0 StyleSheetSybil (talk | contribs) give the limit of quantitation with the signal-to-noise ratio it assumes [rollback]
  4. (diff | hist) m 21:14 Karl Fischer titration 9,318 ±0 CommaCarys (talk | contribs) expand §Chemical basis [rollback]
  5. (diff | hist) m 18:35 Loss on drying 4,874 ±0 ImportRecordIna (talk | contribs) rm the claim that the method is stability-indicating without a forced-degradation study [rollback]
  6. (diff | hist) 17:06 ISO 9001 4,278 ±0 ShortageShona (talk | contribs) correct the description of the research-use-only exemption [rollback]
  7. (diff | hist) 16:52 Reconstitution calculator 8,662 ±0 CoI_Corin (talk | contribs) fix the arithmetic in the second worked example [rollback]
  8. (diff | hist) 14:55 Talk:Dose escalation schedule 885 +158 EscalationEira (talk | contribs) /* Tirzepatide table row */ reply
  9. (diff | hist) 13:55 Talk:Drug master file 748 +66 COA_Colwyn (talk | contribs) /* Same shape as other claims */ reply
  10. (diff | hist) m 12:41 International nonproprietary name 4,356 ±0 DulaglutideDug (talk | contribs) expand §Stems relevant here [rollback]
  11. (diff | hist) 11:20 Talk:Dose escalation schedule 674 +109 TirzTaxonomist (talk | contribs) /* Tirzepatide table row */ new section